Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

PURPOSE: Tumor-derived cell-free DNA (cfDNA) from urine of patients with cancer offers non-invasive biologic material for detection of cancer-related molecular abnormalities such as mutations in Exon 2 of KRAS. EXPERIMENTAL DESIGN: A quantitative, mutation-enrichment next-generation sequencing test...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Fujii, Takeo, Barzi, Afsaneh, Sartore-Bianchi, Andrea, Cassingena, Andrea, Siravegna, Giulia, Karp, Daniel D., Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Huang, Helen J., Veronese, Silvio, Di Nicolantonio, Federica, Pingle, Sandeep, Vibat, Cecile Rose T., Hancock, Saege, Berz, David, Melnikova, Vladislava O., Erlander, Mark G., Luthra, Rajyalakshmi, Kopetz, E. Scott, Meric-Bernstam, Funda, Siena, Salvatore, Lenz, Heinz-Joseph, Bardelli, Alberto, Janku, Filip
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5511562/
https://ncbi.nlm.nih.gov/pubmed/28096270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2592
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados